EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges

 
• By Ian Schofield

COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.

EUFlagPills
The EU is changing the way it charges fees for drug regulatory services • Source: Shutterstock

More from User Fees

More from Pathways & Standards